Completed PHASE3 INTERVENTIONAL NCT00179283

Sertraline vs. Venlafaxine XR

A Multi-center, Randomized, Double-blind, Parallel-group Study of Sertraline vs. Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder

Sponsor: Pfizer

Conditions Major Depressive Disorder

Interventions sertraline venlafaxine XR

Updated 5 times since 2017 Last updated: Jun 1, 2015 Started: Apr 30, 2002 Completion: Apr 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Major Depressive Disorder and is currently completed. Pfizer leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Vanderbilt University

Data source: Vanderbilt University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nashville, United States